We are live on ! Find out more
ARMP icon

Armata Pharmaceuticals
ARMP

26 hedge funds and large institutions have $886K invested in Armata Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

250% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 2

250% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 2

24% more funds holding

Funds holding: 21 → 26 (+5)

40% less capital invested

Capital invested by funds: $1.48M → $886K (-$594K)

Holders
26
Holders Change
+5
Holders Change %
+23.81%
% of All Funds
0.6%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
7
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$132K
2
Renaissance Technologies
Renaissance Technologies
New York
+$43.7K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$41.2K
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$37.1K
5
Citadel Advisors
Citadel Advisors
Florida
+$32.7K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$907K
2
VF
Virtu Financial
New York
-$45K
3
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$42.4K
4
SWP
Stratos Wealth Partners
Ohio
-$3K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
26
Morgan Stanley
New York
– +$81 +5 New
1
2

ARMP Hedge Fund Activity: Q2 2018 in Review

26 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Armata Pharmaceuticals (ARMP) for Q2 2018, worth a combined $886K — down 40% from $1.48M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new ARMP positions and 2 closed out — a net gain of 5 holders — while 7 added to existing stakes and 2 trimmed.

The largest buyer was Vanguard Group, adding an estimated $132K. The largest seller was Sabby Management, exiting entirely with an estimated $907K sold.

  • 26 institutional investors held Armata Pharmaceuticals (ARMP) as of Q2 2018, up from 21 in Q1 2018.
  • Funds reported $886K of Armata Pharmaceuticals stock for Q2 2018, down 40% quarter-over-quarter.
  • 7 funds opened new Armata Pharmaceuticals positions in Q2 2018 and 2 closed out, a net change of +5 holders.
  • The largest Armata Pharmaceuticals buyer in Q2 2018 was Vanguard Group, an estimated $132K added.
  • The largest Armata Pharmaceuticals seller in Q2 2018 was Sabby Management, an estimated $907K sold.

Based on aggregated 13F filings for Q2 2018.